跳轉至內容
Merck
  • Vitamin D deficiency promotes nonalcoholic steatohepatitis through impaired enterohepatic circulation in animal model.

Vitamin D deficiency promotes nonalcoholic steatohepatitis through impaired enterohepatic circulation in animal model.

American journal of physiology. Gastrointestinal and liver physiology (2014-09-13)
Ming Kong, Longdong Zhu, Li Bai, Xiaohui Zhang, Yu Chen, Shuang Liu, Sujun Zheng, Stephen J Pandol, Yuan-Ping Han, Zhongping Duan
摘要

Vitamin D deficiency (VDD) or insufficiency is recognized for its association with nonalcoholic steatohepatitis (NASH), whereas the underlying mechanism remains unknown. Using animal models, we found that vitamin D deficiency promoted the high-fat diet (HFD)-initiated simple steatosis into typical NASH, characterized by elevated hepatic inflammation and fat degeneration. The NASH derived from VDD + HFD was related to poor retention of bile acids in the liver and biliary tree, in line with downregulation of the ileal apical sodium-dependent bile acid cotransporter (iASBT). The impediment of hepatic bile acids by the VDD + HFD mice was related to increased expression of hepatic SREBP-1c and fatty acid synthase, suggesting that VDD may upregulate endogenous fatty acid synthesis into NASH through impaired enterohepatic circulation. Administration of 1,25(OH)2VD3 (calcitriol) corrected the NASH phenotypes in line with restoration of iASBT, promotion of bile filling in the biliary tree, suppression of hepatic lipogenesis, and inflammation. Moreover, administration of a bile acid-sequestering agent suppressed ileal fibroblast growth factor 15 expression, leading to increased iASBT expression to restore bile filling in the liver and biliary tree, which ameliorates steatosis and inflammation in the liver. These results suggest a novel mechanism for NASH development, by which VDD downregulates iASBT expression, resulting in a poor bile acid pool and elevation of hepatic lipogenesis and inflammation. In conclusion, vitamin D and bile acid sequestration may be explored as new strategies to treat or prevent NASH.

材料
產品編號
品牌
產品描述

Sigma-Aldrich
胆钙化醇, ≥98% (HPLC)
Sigma-Aldrich
1α,25-二羟基维生素D3, ≥99% (HPLC)
Supelco
胆钙化固醇(维生素 D3), analytical standard
Supelco
胆钙化醇, Pharmaceutical Secondary Standard; Certified Reference Material
USP
胆钙化醇, United States Pharmacopeia (USP) Reference Standard
Supelco
维生素D3标准液 CRM 溶液, 1 mg/mL in ethanol, ampule of 1 mL, certified reference material, Cerilliant®
Sigma-Aldrich
Vitamin D3 solution, 100 μg/mL in ethanol, 97% (CP)
Sigma-Aldrich
1α,25-二羟基维生素D3, ≥97.0% (HPLC)
Supelco
1α,25-二羟基维生素D2标准液 溶液, 5 μg/mL in ethanol, ampule of 1 mL, certified reference material, Cerilliant®
Sigma-Aldrich
胆钙化醇, meets USP testing specifications
胆钙化醇, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
胆钙化醇, analytical standard
骨化三醇, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
1α,25-Dihydroxyvitamin D2 solution, 50 μg/mL in ethanol, 95% (CP)
Sigma-Aldrich
1α,25-Dihydroxyvitamin D2 solution, 100 μg/mL in ethanol, 95% (CP)